Literature DB >> 18528673

[Long-term disease-related costs 4 years after stroke or TIA in Germany].

Y Winter1, C Wolfram, O Schöffski, R C Dodel, T Back.   

Abstract

BACKGROUND: The economic burden of stroke is considerable. While studies on the costs of acute stroke treatment have been undertaken in Germany, thorough analysis of direct and indirect long-term costs is lacking. PATIENTS AND METHODS: A hospital-based cohort of 151 consecutive patients with stroke or transient ischemic attacks (TIA) was followed up (medical examination and interview) at the end of the 4th year following the cerebrovascular event. Costs were calculated using a bottom-up approach and classified into direct medical and nonmedical costs, indirect costs, and patients' costs.
RESULTS: Non-stroke-related costs (mean +/- standard deviation 4,610+/-9,310 Euros/person) were separated from total costs. Total stroke-related costs of the 4th year after stroke/TIA amounted to 7,670+/-10,250 Euros per person. The cost components were as follows: direct costs 56% (4,320+/-5,740 Euros), indirect costs 31% (2,350+/-2,710 Euros), and patients' payments 13% (1,000+/-4,100 Euros). The annual nationwide costs for the 4th year following stroke or TIA amounted to approximately 3 billion Euros.
CONCLUSION: The considerable size of long-term costs after stroke/TIA is mainly due to direct costs and poses an economic challenge to the German health care system. Patients contribute in a relevant way by their own payments.

Entities:  

Mesh:

Year:  2008        PMID: 18528673     DOI: 10.1007/s00115-008-2505-3

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  22 in total

1.  Cost of stroke in The Netherlands from a societal perspective.

Authors:  S M Evers; G L Engel; A J Ament
Journal:  Stroke       Date:  1997-07       Impact factor: 7.914

2.  Cerebral vascular accidents in patients over the age of 60. II. Prognosis.

Authors:  J RANKIN
Journal:  Scott Med J       Date:  1957-05       Impact factor: 0.729

3.  Cost of stroke in Europe.

Authors:  T Truelsen; M Ekman; G Boysen
Journal:  Eur J Neurol       Date:  2005-06       Impact factor: 6.089

4.  Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project.

Authors:  Peter L Kolominsky-Rabas; Peter U Heuschmann; Daniela Marschall; Martin Emmert; Nikoline Baltzer; Bernhard Neundörfer; Oliver Schöffski; Karl J Krobot
Journal:  Stroke       Date:  2006-03-30       Impact factor: 7.914

5.  Medical resource use and costs of health care after acute stroke in Germany.

Authors:  K Rossnagel; C H Nolte; J Muller-Nordhorn; G J Jungehulsing; D Selim; B Bruggenjurgen; A Villringer; S N Willich
Journal:  Eur J Neurol       Date:  2005-11       Impact factor: 6.089

6.  Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study.

Authors:  G J Hankey; K Jamrozik; R J Broadhurst; S Forbes; P W Burvill; C S Anderson; E G Stewart-Wynne
Journal:  Stroke       Date:  2000-09       Impact factor: 7.914

7.  Cost of stroke in Australia from a societal perspective: results from the North East Melbourne Stroke Incidence Study (NEMESIS).

Authors:  H M Dewey; A G Thrift; C Mihalopoulos; R Carter; R A Macdonell; J J McNeil; G A Donnan
Journal:  Stroke       Date:  2001-10       Impact factor: 7.914

8.  Costs of stroke in Sweden. A national perspective.

Authors:  A Terént; L A Marké; K Asplund; B Norrving; E Jonsson; P O Wester
Journal:  Stroke       Date:  1994-12       Impact factor: 7.914

Review 9.  Lifetime cost of stroke in the United States.

Authors:  T N Taylor; P H Davis; J C Torner; J Holmes; J W Meyer; M F Jacobson
Journal:  Stroke       Date:  1996-09       Impact factor: 7.914

10.  Resource utilization and costs of stroke unit care in Germany.

Authors:  Richard C Dodel; Caroline Haacke; Karin Zamzow; Sven Paweilik; Annika Spottke; Mira Rethfeldt; Uwe Siebert; Wolfgang H Oertel; Oliver Schöffski; Tobias Back
Journal:  Value Health       Date:  2004 Mar-Apr       Impact factor: 5.725

View more
  9 in total

1.  Evaluation of the obesity genes FTO and MC4R and the type 2 diabetes mellitus gene TCF7L2 for contribution to stroke risk: The Mannheim-Heidelberg Stroke Study.

Authors:  Yaroslav Winter; Tobias Back; André Scherag; Jakob Linseisen; Sabine Rohrmann; Oliver Lanczik; Anke Hinney; Susann Scherag; Michael Neumaier; Peter A Ringleb; Richard Dodel; Johannes Hebebrand
Journal:  Obes Facts       Date:  2011-08-01       Impact factor: 3.942

2.  Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis.

Authors:  Wilma Erhardt; Klas Bergenheim; Isabelle Duprat-Lomon; Phil McEwan
Journal:  Clin Drug Investig       Date:  2012-03-01       Impact factor: 2.859

3.  Neuroborreliosis-associated cerebral vasculitis: long-term outcome and health-related quality of life.

Authors:  Tobias Back; Steffi Grünig; Yaroslav Winter; Ulf Bodechtel; Kersten Guthke; Diana Khati; Rüdiger von Kummer
Journal:  J Neurol       Date:  2013-01-18       Impact factor: 4.849

4.  Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy.

Authors:  Karsten Schepelmann; Yaroslav Winter; Annika E Spottke; Detlef Claus; Christoph Grothe; Rolf Schröder; Dieter Heuss; Stefan Vielhaber; Veit Mylius; Reinhard Kiefer; Bertold Schrank; Wolfgang H Oertel; Richard Dodel
Journal:  J Neurol       Date:  2009-07-24       Impact factor: 4.849

5.  [Cost of illness and health service patterns in Morbus Parkinson in Austria].

Authors:  Sonja von Campenhausen; Yaroslav Winter; Julia Gasser; Klaus Seppi; Jens-P Reese; Karl-P Pfeiffer; Sabine Geiger-Gritsch; Kai Bötzel; Uwe Siebert; Wolfgang H Oertel; Richard Dodel; Werner Poewe
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

6.  Evaluation of costs and outcome in cardioembolic stroke or TIA.

Authors:  Yaroslav Winter; Caroline Wolfram; Matthias Schaeg; Jens-Peter Reese; Wolfgang H Oertel; Richard Dodel; Tobias Back
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

7.  A population-based study of hospital care costs during 5 years after transient ischemic attack and stroke.

Authors:  Ramon Luengo-Fernandez; Alastair M Gray; Peter M Rothwell
Journal:  Stroke       Date:  2012-11-15       Impact factor: 7.914

Review 8.  The global impact of non-communicable diseases on healthcare spending and national income: a systematic review.

Authors:  Taulant Muka; David Imo; Loes Jaspers; Veronica Colpani; Layal Chaker; Sven J van der Lee; Shanthi Mendis; Rajiv Chowdhury; Wichor M Bramer; Abby Falla; Raha Pazoki; Oscar H Franco
Journal:  Eur J Epidemiol       Date:  2015-01-18       Impact factor: 8.082

9.  Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany.

Authors:  Ulrike Theidel; Christian Asseburg; Evangelos Giannitsis; Hugo Katus
Journal:  Clin Res Cardiol       Date:  2013-03-09       Impact factor: 5.460

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.